Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 μg) in women with postmenopausal symptoms: Updated analysis of three randomized, controlled trials

Clinical Therapeutics

Volumn 28, Issue 6, 2006, Pages 921-932

  Rowan, Jean P ^a   Simon, James A ^b   Speroff, Leon ^c   Ellman, Herman ^d  

^a Parke Davis   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Warner Chilcott Inc   (United States)

Author keywords

ethinyl estradiol; hormone therapy; low dose; norethindrone acetate; osteoporosis; post menopausal women; vasomotor symptoms

Indexed keywords

ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; PLACEBO;

ABDOMINAL PAIN; ADULT; AMENORRHEA; ARTHRALGIA; ARTICLE; BONE DENSITY; CAUCASIAN; CLINICAL LABORATORY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EDEMA; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; EXPERIENCE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FREQUENCY ANALYSIS; GYNECOLOGICAL EXAMINATION; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; MEDICAL RECORD; MENOPAUSAL SYNDROME; MULTICENTER STUDY; NAUSEA AND VOMITING; PHYSICAL EXAMINATION; POST HOC ANALYSIS; PRACTICE GUIDELINE; PUBLICATION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECORDING; SCORING SYSTEM; SELF REPORT; STANDARD; URINARY TRACT INFECTION; VAGINA BLEEDING; VAGINA SECRETION; VAGINITIS; VASOMOTOR DISORDER;

BONE DENSITY; ENDOMETRIAL HYPERPLASIA; ESTROGEN REPLACEMENT THERAPY; ETHINYL ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS;

EID: 33746151199     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.06.013     Document Type: Article

References (15)

1. North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and post-menopausal women: October 2004 position statement of The North American Menopause Society. Menopause 11 (2004) 589-600
2. (Suppl). American College of Obstetricians and Gynecologists Women's Health Care Physicians. Vasomotor symptoms. Obstet Gynecol 104 (2004) 1065-1175
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
4. Archer D.F. Low-dose hormone therapy for postmenopausal women. Clin Obstet Gynecol 46 (2003) 317-324
5. Draft Guidance, January. Guidance for Industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation. Accessed September 7, 2005 (2003). http://www.fda.gov/cder/guidance/5412dft.pdf Accessed September 7, 2005
6. Speroff L., Symons J., Kempfert N., Rowan J., and femhrt Study Investigators. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. Menopause 7 (2000) 383-390
7. Symons J., Kempfert N., Speroff L., and FemHRT Study Investigators. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. Obstet Gynecol 96 (2000) 366-372
8. Speroff L., Rowan J., Symons J., et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 276 (1996) 1397-1403
9. Crandall C. Low-dose estrogen therapy for menopausal women: A review of efficacy and safety. J Womens Health (Larchmt) 12 (2003) 723-747
10. North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: Position statement of The North American Menopause Society. Menopause 10 (2003) 113-132
11. Lindsay R., Gallagher J.C., Kleerekoper M., and Pickar J.H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early post-menopausal women. JAMA 287 (2002) 2668-2676
12. Rubinacci A., Peruzzi E., Modena A.B., et al. Effect of low-dose transdermal E2/NETA on the reduction of post menopausal bone loss in women. Menopause 10 (2003) 241-249
13. Ettinger B., Ensrud K.E., Wallace R., et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstet Gynecol 104 (2004) 443-451
14. Oldenhave A., Jaszmann L.J., Haspels A.A., and Everaerd W.T. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 168 (1993) 772-780
15. [published correction appears in Maturitas. 1988;10:363]. Berg G., Gottwall T., Hammar M., and Lindgren R. Climacteric symptoms among women aged 60-62 in Linkoping, Sweden, in 1986. Maturitas 10 (1988) 193-199